Cardiovascular effects of thiazolidinediones

Pitiporn Suwattee, Cyrus DeSouza, Sunil Asnani, Lucia Gilling, Vivian A. Fonseca

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


The thiazolidinediones are a new class of compounds approved for the treatment of type 2 diabetes. Because these drugs directly improve insulin resistance and decrease plasma insulin concentration, they have the potential to decrease the risk for cardiovascular disease in diabetic patients. A number of studies have demonstrated changes in several cardiovascular risk factors associated with the insulin resistance syndrome. These effects include decreasing of blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. Other in vitro effects related to their ability to bind a newly described class of receptors (peroxisome proliferator-activated receptors) may also have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. The implications of these changes are not clear. Because of their mechanism of action, clinical trials have been designed to determine whether these drugs (or similar "insulin sensitizers") will decrease cardiovascular events in people with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)126-134
Number of pages9
Issue number2
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Cardiovascular effects of thiazolidinediones'. Together they form a unique fingerprint.

Cite this